Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 11/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5515766 | 0.81 | OPRM1 (0.53) | OPRM1ALDH1A1PTGDR2 | |
| SCHEMBL10893728 | 0.80 | TRPM8 (0.55) | OPRM1ALDH1A1LMNA | |
| SCHEMBL3083064 | 0.77 | OPRM1 (0.73) | OPRM1 | |
| SCHEMBL18116775 | 0.77 | OPRM1 (0.57) | OPRM1ALOX5ALDH1A1 | |
| SCHEMBL3199341 | 0.76 | OPRM1 (0.54) | OPRM1ALDH1A1LMNA | |
| SCHEMBL10693309 | 0.76 | ALOX5 (0.58) | OPRM1CHRM5CHRM1CHRM3ALOX5 | |
| SCHEMBL11807879 | 0.75 | CYP3A4 (0.54) | CHRM5CHRM1CHRM3ALDH1A1 | |
| SCHEMBL6319991 | 0.74 | HTR2A (0.51) | OPRM1ALDH1A1LMNAPTGDR2 | |
| SCHEMBL5105099 | 0.74 | SLC2A4 (0.55) | OPRM1CHRM1CHRM3ALOX5PTGDR2 | |
| SCHEMBL21785057 | 0.73 | OPRM1 (0.49) | OPRM1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908931-B2 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040235891-A1 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235891-A1 | Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists | MTNR1A, MTNR1B, PER2 | OPRM1 84/4885CHRM5 444/4885CHRM1 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.